

Catalog # 10-4784 **Fruguintinib**

CAS# 1194506-26-7

6-(6,7-Dimethoxyguinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide; HMPL-013 Lot # FBS2019

Fruquintinib is a potent and highly selective inhibitor of VEGFR kinase (IC₅₀'s: VEGFR1= 33 nM, VEGFR2 = 35 nM, VEGFR3 = 0.5 nM).1 It potently inhibited VEGF/VEGFR signaling and cell proliferation in HUVECs and HLECs and prevented angiogenesis in vitro. Fruquintinib is currently is several clinical trials against metastatic colorectal cancer² and nonsquamous non-small-cell lung cancer³.

- 1) Sun et al. (2014) Discovery of fruguintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy; Cancer Biol. Ther. 15 1635
- 2) Li et al. (2018) Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial; JAMA 319 2486
- Lu et al. (2018) Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer; J. Clin. Oncol. 36 1207

PHYSICAL DATA

Molecular Weight: 393.40 Molecular Formula: C21H19N3O4 Purity: >98% by HPLC NMR: (Conforms)

DMSO (5 mg/ml)

Solubility: Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.